Literature DB >> 21991892

Changes in forced expiratory volume in 1 second over time in COPD.

Jørgen Vestbo1, Lisa D Edwards, Paul D Scanlon, Julie C Yates, Alvar Agusti, Per Bakke, Peter M A Calverley, Bartolome Celli, Harvey O Coxson, Courtney Crim, David A Lomas, William MacNee, Bruce E Miller, Edwin K Silverman, Ruth Tal-Singer, Emiel Wouters, Stephen I Rennard.   

Abstract

BACKGROUND: A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated rate of decline in forced expiratory volume in 1 second (FEV(1)), but data on the variability and determinants of this change in patients who have established disease are scarce.
METHODS: We analyzed the changes in FEV(1) after administration of a bronchodilator over a 3-year period in 2163 patients. A random-coefficient model was used to evaluate possible predictors of both FEV(1) levels and their changes over time.
RESULTS: The mean (±SE) rate of change in FEV(1) was a decline of 33±2 ml per year, with significant variation among the patients studied. The between-patient standard deviation for the rate of decline was 59 ml per year. Over the 3-year study period, 38% of patients had an estimated decline in FEV(1) of more than 40 ml per year, 31% had a decline of 21 to 40 ml per year, 23% had a change in FEV(1) that ranged from a decrease of 20 ml per year to an increase of 20 ml per year, and 8% had an increase of more than 20 ml per year. The mean rate of decline in FEV(1) was 21±4 ml per year greater in current smokers than in current nonsmokers, 13±4 ml per year greater in patients with emphysema than in those without emphysema, and 17±4 ml per year greater in patients with bronchodilator reversibility than in those without reversibility.
CONCLUSIONS: The rate of change in FEV(1) among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21991892     DOI: 10.1056/NEJMoa1105482

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  318 in total

1.  Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene.

Authors:  Jin Hwa Lee; Michael H Cho; Merry-Lynn N McDonald; Craig P Hersh; Peter J Castaldi; James D Crapo; Emily S Wan; Jennifer G Dy; Yale Chang; Elizabeth A Regan; Megan Hardin; Dawn L DeMeo; Edwin K Silverman
Journal:  Respir Med       Date:  2014-08-11       Impact factor: 3.415

Review 2.  Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).

Authors:  Han Ni; Aung Htet; Soe Moe
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

Review 3.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

4.  Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality.

Authors:  Jacob Louis Marott; Truls Sylvan Ingebrigtsen; Yunus Çolak; Jørgen Vestbo; Peter Lange
Journal:  Am J Respir Crit Care Med       Date:  2020-07-15       Impact factor: 21.405

Review 5.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

6.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

7.  Integrated interdisciplinary care for patients with chronic obstructive pulmonary disease reduces emergency department visits, admissions and costs: a quality assurance study.

Authors:  Esther Dajczman; Chantal Robitaille; Pierre Ernst; Andrew Michael Hirsch; Norman Wolkove; David Small; Judy Bianco; Hartley Stern; Mark Palayew
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

8.  Clinical Features according to the Frequency of Acute Exacerbation in COPD.

Authors:  Seung Jun Lee; Seung Hun Lee; Yu Eun Kim; Yu Ji Cho; Yi Yeong Jeong; Ho Cheol Kim; Jin Hyun Kim; Jin Jong You; Chul-Ho Yoon; Jong Deog Lee; Young Sil Hwang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30

9.  Factors Associated With Progression of Lung Function Abnormalities in HIV-Infected Individuals.

Authors:  Yijia Li; Seyed Mehdi Nouraie; Cathy Kessinger; Renee Weinman; Laurence Huang; Ruth M Greenblatt; Eric Kleerup; Lawrence Kingsley; Deborah McMahon; Meghan Fitzpatrick; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

10.  Serum concentrations of club cell secretory protein (Clara) and cancer mortality in adults: a population-based, prospective cohort study.

Authors:  Stefano Guerra; Monica M Vasquez; Amber Spangenberg; Marilyn Halonen; Fernando D Martinez
Journal:  Lancet Respir Med       Date:  2013-11-15       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.